Van den Eynde V, Parker G, Ruhe H, Birkenhager T, Godet L, Shorter E
Psychopharmacol Bull. 2023; 53(3):35-54.
PMID: 37601082
PMC: 10434306.
Crisan C, Milhem Z, Stretea R, Tata I, Chereches R, Miclutia I
J Pers Med. 2023; 13(2).
PMID: 36836540
PMC: 9960519.
DOI: 10.3390/jpm13020306.
Khan A, Mar K, Brown W
Psychopharmacol Bull. 2021; 51(3):79-108.
PMID: 34421147
PMC: 8374926.
Khan A, Mar K, Brown W
Int Clin Psychopharmacol. 2018; 33(5):239-248.
PMID: 29939890
PMC: 6078483.
DOI: 10.1097/YIC.0000000000000229.
Fekadu A, Donocik J, Cleare A
BMC Psychiatry. 2018; 18(1):100.
PMID: 29642877
PMC: 5896127.
DOI: 10.1186/s12888-018-1679-x.
Marketing medicines: charting the rise of modern therapeutics through a systematic review of adverts in UK medical journals (1950-1980).
Green A, Haddad P, Aronson J
Br J Clin Pharmacol. 2018; 84(8):1668-1685.
PMID: 29442380
PMC: 6046508.
DOI: 10.1111/bcp.13549.
Against the stream: Antidepressants are not antidepressants - an alternative approach to drug action and implications for the use of antidepressants.
Moncrieff J
BJPsych Bull. 2018; 42(1):42-44.
PMID: 29388527
PMC: 6001865.
DOI: 10.1192/bjb.2017.11.
Antidepressants versus placebo in major depression: an overview.
Khan A, Brown W
World Psychiatry. 2015; 14(3):294-300.
PMID: 26407778
PMC: 4592645.
DOI: 10.1002/wps.20241.
How do we re-engage the pharmaceutical industry in research on serotonin and psychiatric disorders?.
Green A, Marsden C
ACS Chem Neurosci. 2013; 4(1):9-12.
PMID: 23336037
PMC: 3547478.
DOI: 10.1021/cn3001894.
Sex-dependent modulation of treatment response.
Rubinow D, Moore M
Dialogues Clin Neurosci. 2011; 6(1):39-51.
PMID: 22034399
PMC: 3181787.
Electroconvulsive therapy: Part I. A perspective on the evolution and current practice of ECT.
Payne N, Prudic J
J Psychiatr Pract. 2009; 15(5):346-68.
PMID: 19820553
PMC: 3042260.
DOI: 10.1097/01.pra.0000361277.65468.ef.
Gaddum and LSD: the birth and growth of experimental and clinical neuropharmacology research on 5-HT in the UK.
Green A
Br J Pharmacol. 2008; 154(8):1583-99.
PMID: 18516072
PMC: 2518468.
DOI: 10.1038/bjp.2008.207.
Selective serotonin reuptake inhibitors: evidence base for older antidepressants is shaky too.
Moncrieff J
BMJ. 2005; 330(7488):420.
PMID: 15718554
PMC: 549124.
DOI: 10.1136/bmj.330.7488.420.
The role of monoamine oxidase inhibitors in current psychiatric practice.
Fiedorowicz J, Swartz K
J Psychiatr Pract. 2004; 10(4):239-48.
PMID: 15552546
PMC: 2075358.
DOI: 10.1097/00131746-200407000-00005.
The electroconvulsive therapy controversy: evidence and ethics.
Reisner A
Neuropsychol Rev. 2004; 13(4):199-219.
PMID: 15000226
DOI: 10.1023/b:nerv.0000009484.76564.58.
Active placebos versus antidepressants for depression.
Moncrieff J, Wessely S, Hardy R
Cochrane Database Syst Rev. 2004; (1):CD003012.
PMID: 14974002
PMC: 8407353.
DOI: 10.1002/14651858.CD003012.pub2.
Comprehensive survey of the relationship between serum concentration and therapeutic effect of amitriptyline in depression.
Ulrich S, Lauter J
Clin Pharmacokinet. 2002; 41(11):853-76.
PMID: 12190332
DOI: 10.2165/00003088-200241110-00004.
Brofaromine--a review of its pharmacological properties and therapeutic use.
Volz H, Gleiter C, Waldmeier P, Struck M, Moller H
J Neural Transm (Vienna). 1996; 103(1-2):217-45.
PMID: 9026374
DOI: 10.1007/BF01292628.
Risk-benefit assessment of newer versus older monoamine oxidase (MAO) inhibitors.
Lecrubier Y
Drug Saf. 1994; 10(4):292-300.
PMID: 8018301
DOI: 10.2165/00002018-199410040-00003.
A risk-benefit assessment of moclobemide in the treatment of depressive disorders.
Norman T, Burrows G
Drug Saf. 1995; 12(1):46-54.
PMID: 7741983
DOI: 10.2165/00002018-199512010-00004.
